Table 1.
Baseline characteristics comparing participants who were on statins at admission with those who were not on statins.
| Not on statins at admission | On statins at admission | Overall | p-value | |
|---|---|---|---|---|
| Characteristics | ||||
| Number of participants, n (%) | 139 (54.5) | 116 (45.5) | 255 | |
| Age in years, mean (SD) | 62.4 (17.7) | 69 (10.6) | 65.4 (15.2) | <0.001 |
| Female gender, n (%) | 68 (48.9) | 57 (49.1) | 125 (49) | 0.972 |
| African American race, n (%) | 76 (54.7) | 77 (66.4) | 153 (60) | 0.057 |
| Body mass index in kg/m2, mean (SD) | 29.7 (8.3) | 29.4 (9.9) | 29.5 (9.1) | 0.811 |
| Asthma, n (%) | 9 (6.5) | 10 (8.6) | 19 (7.4) | 0.516 |
| COPD, n (%) | 15 (10.8) | 17 (14.7) | 32 (12.5) | 0.354 |
| Cirrhosis, n (%) | 6 (4.3) | 3 (2.6) | 9 (3.5) | 0.456 |
| Diabetes mellitus, n (%) | 49 (35.2) | 74 (63.8) | 123 (48.2) | <0.001 |
| End stage renal disease, n (%) | 4 (2.9) | 16 (13.8) | 20 (7.8) | 0.001 |
| Coronary artery disease, n (%) | 7 (5) | 39 (33.6) | 46 (18) | <0.001 |
| Hypertension, n (%) | 85 (61.1) | 102 (87.9) | 187 (73.3) | <0.001 |
| SOFA on admission, mean (SD) | 3.4 (3.6) | 4.4 (3.5) | 3.9 (3.6) | 0.13 |
| PaO2: FiO2 ratio | 278.6 (153.3) | 268 (164.6) | 274.3 (157.5) | 0.704 |
| Home Medications | ||||
| Antiplatelets, n (%) | 29 (20.8) | 66 (56.9) | 95 (37.2) | <0.001 |
| ACEI/ARB, n (%) | 33 (23.7) | 54 (46.5) | 87 (34.1) | <0.001 |
| NSAIDs, n (%) | 11 (7.9) | 10 (8.7) | 21 (8.3) | 0.822 |
| Home anticoagulation, n (%) | 18 (12.9) | 19 (16.4) | 37 (14.5) | 0.439 |
| Prednisone, n (%) | 13 (9.3) | 5 (4.3) | 18 (7.1) | 0.117 |
Abbreviations: SOFA, Sequential Organ Failure Assessment; ACEI, Angiotensin converting enzyme inhibitor; ARB, Angiotensin receptor blocker; NSAID, Non-steroidal anti-inflammatory drug.